BioMarin, Sanofi tap new execs for early R&D positions

BioMarin and Sanofi each have new leaders of their early R&D teams, as the biotech has made a high-profile hire while the French pharma has promoted from within to replace two executives who are leaving the company.

BioMarin Pharmaceutical Co. Inc. (NASDAQ:BMRN) hired Harvard professor and serial entrepreneur Kevin Eggan as its group VP and head of research and early development. Eggan is a professor in Harvard’s stem cell and regenerative biology department, as well as director of stem cell biology at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard...